The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) held its Fall meeting on November 1st, 2018 via teleconference. All 12 IHS Areas were represented. Jorge Mera, MD, Director, Infectious Diseases for the Cherokee Nation and Paulina Deming, PharmD, Associate Professor, University of New Mexico College of Pharmacy served as clinical speakers. Ann Bullock, MD, Director, IHS Division of Diabetes Treatment and Prevention also attended as a subject matter expert. Affiliates from the Veterans Health Administration, Department of Defense, and Federal Bureau of Prisons provided information on formulary updates, clinical experiences and future meetings from their respective agencies. The NPTC values the relationships with its field experts, subject matter experts and federal partners and appreciates the opportunity to host this from the IHS Oklahoma City Area Office.

The NPTC presentations consisted of a comprehensive review of chronic Hepatitis C Virus (HCV) infection, including a review of HCV Pharmacotherapy and an update of HCV Guidelines/Best Treatment Practices. A brief review of basal insulins, specifically insulin detemir and glargine, was also delivered.

The resulting action(s) from the meeting were as follows:

1. Two clinical presentations on Hepatitis C Virus (HCV) infection were provided to the NPTC. The first presentation focused on currently available pharmacotherapeutic options for HCV and included comparisons of drug-specific details (e.g., pharmacokinetics, adverse drug events, etc.) as well as clinical trial findings/patient outcomes. The second presentation reviewed the current treatment guidelines and best practices from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Supplemental analyses on IHS medication procurement & utilization trends, in addition to IHS health visit and prescription data from the IHS National Data Warehouse, added perspective. Ultimately, the NPTC voted to ADD (1.) glecaprivir-pibrentasvir (Mavyret®), (2.) sofosbuvir-velpatasvir (Epclusa®), and (3.) ledipasvir-sofosbuvir (Harvoni®) to the National Core Formulary (NCF). As customary, the NPTC will produce and disseminate a NPTC Formulary Brief, which will include key outcomes and decisional data guiding the formulary decision(s).

2. An abbreviated clinical review, in conjunction with a detailed pharmacoeconomic analysis, of the basal insulins, detemir and glargine was delivered. Insulin detemir (Levemir®) is currently the sole basal insulin named on the National Core Formulary. Comparative clinical outcomes, IHS utilization rates, and provider preferences were shared offering substantial value in the formulary decision. Following extensive discussion, the NPTC voted to ADD insulin glargine (Lantus®) in addition to insulin detemir to the NCF. This decision extends to both glargine vials and pen devices.

**The next NPTC meeting will be the 2019 Winter Meeting, scheduled for February 5-6th, 2019. The Winter agenda will include treatment reviews for Alzheimer’s and Parkinson’s disease, and drug class reviews of both SSRIs and SNRIs for depression/general anxiety disorder, Dipeptidyl Peptidase (DPP)-4 Inhibitors and anti-muscarinic agents for overactive bladder/urge incontinence.**

For more information about the NPTC or National Core Formulary, please visit the NPTC website.